Search results
PROMOTED
Author(s):
Jasper J Brugts
Added:
1 month ago
Watch our video collection following the late-breaking science sessions from the ESC Heart Failure Association's 2025 congress. Our Expert Interviews provide insights on the hottest data and key take-home messages from the most influential trials.
View more
ESC HF 2025 Late-Breaking Science Collection
Video Series
Author(s):
Giuseppe Rosano
,
Harriette Van Spall
Added:
1 year ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Author(s):
C Noah Nilsson
,
Mads Kristian Ersbøll
,
Finn Gustafsson
Added:
9 months ago
Author(s):
Harriette Van Spall
,
Roland RJ van Kimmenade
Added:
2 months ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Author(s):
Jasper J Brugts
Added:
1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,…
View more
Author(s):
Stephen J Greene
Added:
1 month ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an…
View more
Author(s):
Antonio Luca Maria Parlati
,
Cristina Madaudo
,
Vincenzo Nuzzi
,
et al
Added:
4 months ago
Author(s):
Renzo Laborante
,
Attilio Restivo
,
Daniela Mele
,
et al
Added:
1 month ago
Author(s):
Moza A Alzaabi
,
Amin Abdelsalam
,
Majid Alhammadi
,
et al
Added:
1 year ago
Author(s):
Karol Mirkowski
,
Ercole Vellone
,
Bernadetta Żółkowska
,
et al
Added:
3 months ago